Mozart Therapeutics, Inc.

Orchestrating the Immune System

Add To Watchlist
General Information
Company Name
Mozart Therapeutics, Inc.
Founded Year
2020
Location (Offices)
Seattle, United States +1
Founders / Decision Makers
Kristine Swiderek - Chief Scientific Officer Katie Fanning - President & Chief Executive Officer Jan Beck - Chief Operating Officer Mark Davis - Founder Jason Chien - Chief Medical Officer Russ Hawkinson - Chief Financial Officer
Number of Employees
41
Industries
Biotechnology
Funding Stage
Series A
Social Media

Mozart Therapeutics, Inc. - Company Profile

Mozart Therapeutics is a biotechnology startup founded in 2020 with the mission of "Orchestrating the Immune System." The company is focused on developing disease-modifying therapies for autoimmune and inflammatory diseases by targeting a novel regulatory immune pathway. In a recent milestone, Mozart Therapeutics secured a significant $25.00M Series A investment on 07 June 2023. The funding round was led by prominent investors including AbbVie Ventures, Ono Venture Investment, UPMC Enterprises, and Pfizer Venture Investments. With its groundbreaking approach to addressing unmet medical needs in the field, Mozart Therapeutics shows promising potential in revolutionizing immune system therapeutics.

Taxonomy: biopharmaceuticals, immune system, autoimmune diseases, inflammatory diseases, disease-modifying therapies, regulatory immune pathway

Funding Rounds & Investors of Mozart Therapeutics, Inc. (2)

View All
Funding Stage Amount No. Investors Investors Date
Series A $25.00M 4
AbbVie Ventures, investor in Mozart Therapeutics, Inc.'s Series A round Ono Venture Investment, investor in Mozart Therapeutics, Inc.'s Series A round
UPMC Enterprises, Pfizer Venture Investments 		07 Jun 2023
Series A $55.00M 6
Arch Venture Partners, investor in Mozart Therapeutics, Inc.'s Series A round Sofinnova Partners, investor in Mozart Therapeutics, Inc.'s Series A round Alexandria Venture Investments, investor in Mozart Therapeutics, Inc.'s Series A round Eli Lilly, investor in Mozart Therapeutics, Inc.'s Series A round Leaps by Bayer, investor in Mozart Therapeutics, Inc.'s Series A round MRL Ventures Fund, investor in Mozart Therapeutics, Inc.'s Series A round
26 Oct 2021

Latest News of Mozart Therapeutics, Inc.

View All

No recent news or press coverage available for Mozart Therapeutics, Inc..

Similar Companies to Mozart Therapeutics, Inc.

View All
Nuvig Therapeutics Inc. - Similar company to Mozart Therapeutics, Inc.
Nuvig Therapeutics Inc. Rebalancing Immune Function for Chronic Inflammatory and Autoimmune Diseases
Revolo Biotherapeutics - Similar company to Mozart Therapeutics, Inc.
Revolo Biotherapeutics Analyze | Reset | Revolutionize
Thymmune Therapeutics - Similar company to Mozart Therapeutics, Inc.
Thymmune Therapeutics
Delinia - Similar company to Mozart Therapeutics, Inc.
Delinia Pioneering breakthrough treatments for autoimmune and inflammatory diseases with a focus on enhancing regulatory T cells to maintain immune system balance.
Immune Tolerance Network - Similar company to Mozart Therapeutics, Inc.
Immune Tolerance Network The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of
Circle Decoration Circle Decoration

Want to dive deeper into Mozart Therapeutics, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now